ProbeChem®
Expedite Your Scientific Research

WWW.PROBECHEM.COM

Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Product Name	:	CYC065
Cat. No.	:	PC-61248
CAS No.	:	1070790-89-4
Molecular Formula	:	$C_{21}H_{31}N_7O$
Molecular Weight	:	397.527
Target	:	Cyclin-dependent Kinase (CDK)
Solubility	:	DMSO: 100 mg/mL



Biological Activity

CYC065 (Fadraciclib) is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on **CDK2/5/9**.
CYC065 demonstrates cytotoxicity both in MM cell lines sensitive as well as resistant to conventional chemotherapy with IC50 of 0.06-2 uM.
CYC065 blocks cells in the G1 phase and inhibits cell growth specifically in CCNE1-overexpressing USCs.
CYC065 significantly reduces tumour growth in xenografts derived from CCNE1-amplified USCs.
CYC065 shows synergistic effect in vitro and in vivo combined with Taselisib.

References

Cocco E, et al. ***Br J Cancer.*** 2016 Jul 26;115(3):303-11.

Kawakami M, et al. ***J Natl Cancer Inst.*** 2017 Jun 1;109(6).

Thomas AL, et al. ***Cell Cycle.*** 2017 Aug 3;16(15):1453-1464.

Rao SS, et al. ***Oncotarget.*** 2017 Aug 10;8(48):83925-83939.

E-mail: tech@probechem.com